| Catalog No. | HX200026 |
| Brand | abinScience |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 |
| Purity | >95% purity as determined by SDS-PAGE. |
| Isotype | IgG1-lambda |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Target | TACE, Snake venom-like protease, ADAM17, CD156b, CSVP, ADAM 17, Disintegrin and metalloproteinase domain-containing protein 17, TNF-alpha convertase, TNF-alpha-converting enzyme |
| References | 1. Saha N, et al. Characterization of the D8P1C1 Anti-ADAM17 Inhibitory Monoclonal Antibody and Generation of Its Bispecific T-Cell Engager Derivative. Int J Mol Sci. 2026;27(7):2936. Published 2026 Mar 24. [HX200026] 2. Saha N, et al. Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. Transl Oncol. 2022;15(1):101265. [HX200026] 3. Arora S, et al. ADAM Proteases in Cancer: Biological Roles, Therapeutic Challenges, and Emerging Opportunities. Cancers (Basel). 2025;17(10):1703. Published 2025 May 19. [HX200026] |
| Purification | Protein A/G purified from cell culture supernatant. |
| Biological activity | and tumor growth in xenograft models. 89 Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer [1] [2] [3]. . D8P1C1 (10 ug/mL; 4 h) potently inhibits EGFR phosphorylation in MDA-MB-231, HCC-827, OVCAR-3, and SKOV-3 cells [1]. D8P1C1 (0.037 ug/mL; 38 h) inhibits proliferation of triple-negative breast cancer MDA-MB-231 cells with an IC 50 of 0.037 ug/mL [2]. D8P1C1 (0.625-20 ug/mL; 38 h) inhibits proliferation of SKBR-3, HCC-827, LIM1215, U-87 MG, SKOV-3, OVCAR-3, and CAOV-3 cancer cells, with the greatest efficacy observed in HER2-overexpressing breast SKBR-3 cells [2]. D8P1C1 (7.8125-250 uM; 2 h) preferentially binds to ADAM17 expressed on MDA-MB-231, SKBR-3, HCC-827, LIM1215, U-87 MG, OVCAR-3, SKOV-3, and CAOV-3 cancer cells, with binding affinity approximately 6-fold higher than for ADAM17 on HEK293 cells [2]. . Inhibited TNFα shedding by 78%, CX3CL1 shedding by 70%, and Notch1 cleavage (measured as NICD1 release) by 15%. . Showed no significant change in total EGFR levels in most cell lines. D8P1C1 (40 mg/kg; i.p.; bi-weekly; 4 weeks) achieves 25. |
| Endotoxin level | < 10 EU/mg |
| Expression system | Mammalian cells |
| Accession | P78536 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternative name | D8P1C1 |
| Clone ID | D8P1C1 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
Anti-Human TACE/ADAM17 Reference Antibody (D8P1C1, RUO)
Overview
Images
 SDS-PAGE |
SDS-PAGE for Anti-Human CD156b/ADAM17 Reference Antibody (D8P1C1, RUO) |
 Bioactivity |
Detects recombinant human ADAM17 (Cat No.: HX200012) in indirect ELISA. |